BST-236

DRUG4 trials

Sponsors

BioSight Ltd., Groupe Francophone des Myelodysplasies

Conditions

AML, AdultAcute Myeloid LeukemiaMDSMyelodysplastic SyndromesRefractory Acute Myeloid LeukemiaRelapse/Recurrence

Phase 1

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

BioSight Ltd.AML, Adult

Start: 2022-08-17End: 2025-12-01Target: 80Updated: 2023-04-04

Phase 2

Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy

CompletedNCT03435848

BioSight Ltd.Acute Myeloid Leukemia

Start: 2018-08-14End: 2023-03-16Updated: 2023-07-27

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

BioSight Ltd.AML, Adult, MDS, Refractory Acute Myeloid Leukemia +1

Start: 2021-11-14End: 2024-03-14Target: 40Updated: 2023-03-09

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

CompletedNCT04827719

Groupe Francophone des MyelodysplasiesAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2021-05-01End: 2025-01-13Updated: 2026-08-11

Related Papers

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Blood Advances2023-10-30

Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study

Blood2021-11-05

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.

Journal of Clinical Oncology2021-05-201 citations